DK0918545T3 - Tumorbehandling - Google Patents

Tumorbehandling

Info

Publication number
DK0918545T3
DK0918545T3 DK97945975T DK97945975T DK0918545T3 DK 0918545 T3 DK0918545 T3 DK 0918545T3 DK 97945975 T DK97945975 T DK 97945975T DK 97945975 T DK97945975 T DK 97945975T DK 0918545 T3 DK0918545 T3 DK 0918545T3
Authority
DK
Denmark
Prior art keywords
compound
vascular compartment
tumor treatment
mammal
following administration
Prior art date
Application number
DK97945975T
Other languages
English (en)
Inventor
Kenneth Dawson Bagshawe
Original Assignee
Enzacta R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R & D Ltd filed Critical Enzacta R & D Ltd
Application granted granted Critical
Publication of DK0918545T3 publication Critical patent/DK0918545T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK97945975T 1996-11-30 1997-11-28 Tumorbehandling DK0918545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624993.3A GB9624993D0 (en) 1996-11-30 1996-11-30 Tumour therapy
PCT/GB1997/003284 WO1998024478A2 (en) 1996-11-30 1997-11-28 Tumour therapy

Publications (1)

Publication Number Publication Date
DK0918545T3 true DK0918545T3 (da) 2000-11-27

Family

ID=10803777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97945975T DK0918545T3 (da) 1996-11-30 1997-11-28 Tumorbehandling

Country Status (11)

Country Link
EP (1) EP0918545B1 (da)
JP (1) JP2001505220A (da)
AT (1) ATE194499T1 (da)
CA (1) CA2273218A1 (da)
DE (1) DE69702527T2 (da)
DK (1) DK0918545T3 (da)
ES (1) ES2150286T3 (da)
GB (1) GB9624993D0 (da)
GR (1) GR3034592T3 (da)
PT (1) PT918545E (da)
WO (1) WO1998024478A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9812550D0 (en) * 1998-06-11 1998-08-05 Aepact Ltd Tumour therapy and imaging
WO2003055527A2 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
PT3377103T (pt) 2015-11-19 2021-05-26 Revitope Ltd Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
JP2000502698A (ja) * 1995-12-29 2000-03-07 エンザクタ アール アンド ディ リミテッド 細胞毒性試薬

Also Published As

Publication number Publication date
PT918545E (pt) 2000-12-29
JP2001505220A (ja) 2001-04-17
EP0918545B1 (en) 2000-07-12
DE69702527T2 (de) 2001-03-08
ES2150286T3 (es) 2000-11-16
ATE194499T1 (de) 2000-07-15
WO1998024478A2 (en) 1998-06-11
CA2273218A1 (en) 1998-06-11
EP0918545A2 (en) 1999-06-02
WO1998024478A3 (en) 1998-07-30
GB9624993D0 (en) 1997-01-15
GR3034592T3 (en) 2001-01-31
DE69702527D1 (de) 2000-08-17

Similar Documents

Publication Publication Date Title
NO944997L (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
NO996120L (no) Imidazolyl-cykliske acetaler
MY122383A (en) Cyclic boroproline compounds
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
NZ334691A (en) Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DK0918545T3 (da) Tumorbehandling
ATE203016T1 (de) Cryptophycine
IL135921A0 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
NO974275L (no) Fremgangsmåte for behandling av tumorer
FI904521A0 (fi) Komposition foer inducering av sammanbindning.
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
WO2003105774A3 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS THEREOF
TR200501763T2 (tr) Tedavi ve ilaç tarama yöntemleri
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
EP0664281A4 (da)
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
WO1996007421A3 (en) An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor
RU99122488A (ru) Способ лечения рака эндометрия
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
DK0887404T3 (da) Gen, som bibringer selektiv proliferationsaktivitet